MedVector (Reg CF) | StartEngine

CLOSED

GET A PIECE OF MEDVECTOR

A clinical trial could save your life…

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Company Image

</noscript><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-GTM-KQZCQNP" height="0" width="0" style="display: none; visibility: hidden;" /></noscript><script src="https://d10baati43jr8c.cloudfront.net/_next/static/chunks/webpack-2cd5600f7f7543ed.js" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0]);self.__next_f.push([2,null])</script><script>self.__next_f.push([1,"1:HL[\"https://d10baati43jr8c.cloudfront.net/_next/static/css/8c6d8e89db1b876a.css\",\"style\"]\n"])</script><script>self.__next_f.push([1,"2:I[14360,[],\"\"]\n4:I[81317,[\"5878\",\"static/chunks/9da6db1e-9169ed64657e6864.js\",\"470\",\"static/chunks/668bd8de-6ec84d85db960601.js\",\"8760\",\"static/chunks/c473e9eb-b152521f8f339159.js\",\"6631\",\"static/chunks/8c82368a-d72c5658ab9f6a28.js\",\"161\",\"static/chunks/0b216c82-a199d56bfdf3cb5a.js\",\"5042\",\"static/chunks/2b0f660e-4b9f1787362c5b34.js\",\"4358\",\"static/chunks/bc9e92e6-c3262bc18bd04989.js\",\"4533\",\"static/chunks/d441faa4-d842044025885ba0.js\",\"2544\",\"static/chunks/2cea0ef4-1e49e852888961e4.js\",\"1011\",\"static/chunks/1011-41e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"1436\",\"static/chunks/1436-15eb176428e87467.js\",\"4965\",\"static/chunks/4965-f606c91ed72c76bc.js\",\"1460\",\"static/chunks/1460-9f12e0b27390eeec.js\",\"7917\",\"static/chunks/7917-b132173b91dbf639.js\",\"3928\",\"static/chunks/3928-7a4e28f8d12ef4d2.js\",\"1276\",\"static/chunks/1276-05b0f8fd32d71634.js\",\"7552\",\"static/chunks/7552-fffb4e0411ff3161.js\",\"2802\",\"static/chunks/2802-99eef326aadd79e5.js\",\"895\",\"static/chunks/895-392d5ace72c822d2.js\",\"8386\",\"static/chunks/8386-d0882ee23ba2316e.js\",\"5564\",\"static/chunks/5564-342c92fdf012bdd8.js\",\"6916\",\"static/chunks/6916-8c240cbdfa162fcc.js\",\"2400\",\"static/chunks/2400-7c7bf8747130b0c2.js\",\"2615\",\"static/chunks/2615-8cdfb3159fa66a17.js\",\"1338\",\"static/chunks/1338-3f5c3667f246a81d.js\",\"6113\",\"static/chunks/6113-df22ad27d8ec74e5.js\",\"754\",\"static/chunks/754-c0d142adc8d77a4d.js\",\"694\",\"static/chunks/694-d3138f0894c7dc7a.js\",\"5459\",\"static/chunks/5459-511213434c14b424.js\",\"4714\",\"static/chunks/4714-4830fb73fed502a1.js\",\"952\",\"static/chunks/app/offering/%5B%5B...slug%5D%5D/page-d393148abba33621.js\"],\"\"]\n5:\"$Sreact.suspense\"\n6:I[4164,[\"5878\",\"static/chunks/9da6db1e-9169ed64657e6864.js\",\"470\",\"static/chunks/668bd8de-6ec84d85db960601.js\",\"8760\",\"static/chunks/c473e9eb-b152521f8f339159.js\",\"6631\",\"static/chunks/8c82368a-d72c5658ab9f6a28.js\",\"161\",\"static/chunks/0b216c82-a199d56"])</script><script>self.__next_f.push([1,"bfdf3cb5a.js\",\"5042\",\"static/chunks/2b0f660e-4b9f1787362c5b34.js\",\"4358\",\"static/chunks/bc9e92e6-c3262bc18bd04989.js\",\"4533\",\"static/chunks/d441faa4-d842044025885ba0.js\",\"2544\",\"static/chunks/2cea0ef4-1e49e852888961e4.js\",\"1011\",\"static/chunks/1011-41e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"1436\",\"static/chunks/1436-15eb176428e87467.js\",\"4965\",\"static/chunks/4965-f606c91ed72c76bc.js\",\"1460\",\"static/chunks/1460-9f12e0b27390eeec.js\",\"7917\",\"static/chunks/7917-b132173b91dbf639.js\",\"3928\",\"static/chunks/3928-7a4e28f8d12ef4d2.js\",\"1276\",\"static/chunks/1276-05b0f8fd32d71634.js\",\"7552\",\"static/chunks/7552-fffb4e0411ff3161.js\",\"2802\",\"static/chunks/2802-99eef326aadd79e5.js\",\"895\",\"static/chunks/895-392d5ace72c822d2.js\",\"8386\",\"static/chunks/8386-d0882ee23ba2316e.js\",\"5564\",\"static/chunks/5564-342c92fdf012bdd8.js\",\"6916\",\"static/chunks/6916-8c240cbdfa162fcc.js\",\"2400\",\"static/chunks/2400-7c7bf8747130b0c2.js\",\"2615\",\"static/chunks/2615-8cdfb3159fa66a17.js\",\"1338\",\"static/chunks/1338-3f5c3667f246a81d.js\",\"6113\",\"static/chunks/6113-df22ad27d8ec74e5.js\",\"754\",\"static/chunks/754-c0d142adc8d77a4d.js\",\"694\",\"static/chunks/694-d3138f0894c7dc7a.js\",\"5459\",\"static/chunks/5459-511213434c14b424.js\",\"4714\",\"static/chunks/4714-4830fb73fed502a1.js\",\"952\",\"static/chunks/app/offering/%5B%5B...slug%5D%5D/page-d393148abba33621.js\"],\"PreloadCss\"]\n9:I[69257,[],\"\"]\nb:I[14857,[],\"\"]\nd:I[47429,[\"5878\",\"static/chunks/9da6db1e-9169ed64657e6864.js\",\"470\",\"static/chunks/668bd8de-6ec84d85db960601.js\",\"1011\",\"static/chunks/1011-41e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"1436\",\"static/chunks/1436-15eb176428e87467.js\",\"4965\",\"static/chunks/4965-f606c91ed72c76bc.js\",\"1460\",\"static/chunks/1460-9f12e0b27390eeec.js\",\"6327"])</script><script>self.__next_f.push([1,"\",\"static/chunks/6327-f7792d13e65d135c.js\",\"1276\",\"static/chunks/1276-05b0f8fd32d71634.js\",\"7552\",\"static/chunks/7552-fffb4e0411ff3161.js\",\"7213\",\"static/chunks/7213-8d5a3605c97d38cc.js\",\"2400\",\"static/chunks/2400-7c7bf8747130b0c2.js\",\"2801\",\"static/chunks/2801-e4c70d0bbd17012e.js\",\"8412\",\"static/chunks/8412-12ccaf9f2b652271.js\",\"1622\",\"static/chunks/1622-fe15e70f42096ea6.js\",\"7023\",\"static/chunks/7023-50a07cab75a1f42a.js\",\"3185\",\"static/chunks/app/layout-809685d32afd4b50.js\"],\"default\"]\ne:I[91622,[\"5878\",\"static/chunks/9da6db1e-9169ed64657e6864.js\",\"470\",\"static/chunks/668bd8de-6ec84d85db960601.js\",\"8760\",\"static/chunks/c473e9eb-b152521f8f339159.js\",\"6631\",\"static/chunks/8c82368a-d72c5658ab9f6a28.js\",\"4358\",\"static/chunks/bc9e92e6-c3262bc18bd04989.js\",\"4533\",\"static/chunks/d441faa4-d842044025885ba0.js\",\"2544\",\"static/chunks/2cea0ef4-1e49e852888961e4.js\",\"5806\",\"static/chunks/6fdfb389-e0bfed8af5bda3fa.js\",\"1011\",\"static/chunks/1011-41e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"1436\",\"static/chunks/1436-15eb176428e87467.js\",\"4965\",\"static/chunks/4965-f606c91ed72c76bc.js\",\"1460\",\"static/chunks/1460-9f12e0b27390eeec.js\",\"6327\",\"static/chunks/6327-f7792d13e65d135c.js\",\"7917\",\"static/chunks/7917-b132173b91dbf639.js\",\"3928\",\"static/chunks/3928-7a4e28f8d12ef4d2.js\",\"6014\",\"static/chunks/6014-80fe6d0d837f872d.js\",\"1276\",\"static/chunks/1276-05b0f8fd32d71634.js\",\"7552\",\"static/chunks/7552-fffb4e0411ff3161.js\",\"2802\",\"static/chunks/2802-99eef326aadd79e5.js\",\"895\",\"static/chunks/895-392d5ace72c822d2.js\",\"8386\",\"static/chunks/8386-d0882ee23ba2316e.js\",\"6916\",\"static/chunks/6916-8c240cbdfa162fcc.js\",\"2400\",\"static/chunks/2400-7c7bf8747130b0c2.js\",\"2615\",\"static/chunks/2615-8cdfb3159fa66a17.js\",\"1338\",\"static/chunks/1338-3f5c3667f246a81d.js\",\"754\",\"static/chunks/754-c0d142adc8d77a4d.js\",\"694\",\"static/chunks/694-d3138f0894c7dc7a.js\",\"564\",\"static/chunks/564-b9d15c"])</script><script>self.__next_f.push([1,"b11e0a6f23.js\",\"4714\",\"static/chunks/4714-4830fb73fed502a1.js\",\"1931\",\"static/chunks/app/page-b2e0b88c4d29cd96.js\"],\"default\"]\n10:I[87512,[\"5878\",\"static/chunks/9da6db1e-9169ed64657e6864.js\",\"470\",\"static/chunks/668bd8de-6ec84d85db960601.js\",\"8760\",\"static/chunks/c473e9eb-b152521f8f339159.js\",\"6631\",\"static/chunks/8c82368a-d72c5658ab9f6a28.js\",\"4358\",\"static/chunks/bc9e92e6-c3262bc18bd04989.js\",\"4533\",\"static/chunks/d441faa4-d842044025885ba0.js\",\"2544\",\"static/chunks/2cea0ef4-1e49e852888961e4.js\",\"5806\",\"static/chunks/6fdfb389-e0bfed8af5bda3fa.js\",\"1011\",\"static/chunks/1011-41e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"1436\",\"static/chunks/1436-15eb176428e87467.js\",\"4965\",\"static/chunks/4965-f606c91ed72c76bc.js\",\"1460\",\"static/chunks/1460-9f12e0b27390eeec.js\",\"6327\",\"static/chunks/6327-f7792d13e65d135c.js\",\"7917\",\"static/chunks/7917-b132173b91dbf639.js\",\"3928\",\"static/chunks/3928-7a4e28f8d12ef4d2.js\",\"6014\",\"static/chunks/6014-80fe6d0d837f872d.js\",\"1276\",\"static/chunks/1276-05b0f8fd32d71634.js\",\"7552\",\"static/chunks/7552-fffb4e0411ff3161.js\",\"2802\",\"static/chunks/2802-99eef326aadd79e5.js\",\"895\",\"static/chunks/895-392d5ace72c822d2.js\",\"8386\",\"static/chunks/8386-d0882ee23ba2316e.js\",\"6916\",\"static/chunks/6916-8c240cbdfa162fcc.js\",\"2400\",\"static/chunks/2400-7c7bf8747130b0c2.js\",\"2615\",\"static/chunks/2615-8cdfb3159fa66a17.js\",\"1338\",\"static/chunks/1338-3f5c3667f246a81d.js\",\"754\",\"static/chunks/754-c0d142adc8d77a4d.js\",\"694\",\"static/chunks/694-d3138f0894c7dc7a.js\",\"564\",\"static/chunks/564-b9d15cb11e0a6f23.js\",\"4714\",\"static/chunks/4714-4830fb73fed502a1.js\",\"1931\",\"static/chunks/app/page-b2e0b88c4d29cd96.js\"],\"\"]\n13:I[28444,[\"6470\",\"static/chunks/app/global-error-7df69da5ec76f2dc.js\"],\"default\"]\na:[\"slug\",\"medvector\",\"oc\"]\nc:T415,\n /* Define Owners Wide with fallbacks */\n .owners-wide-font {\n font-family: 'owners-"])</script><script>self.__next_f.push([1,"wide', 'IBM Plex Sans', sans-serif;\n font-weight: 700; /* Ensure consistent weight even with fallbacks */\n }\n \n /* Added style for wide/expanded text when Adobe font is unavailable */\n .wf-inactive .owners-wide-font {\n letter-spacing: 0.05em; /* Slightly more tracking when using fallback */\n }\n \n /* Alternative styles for headings when using fallback */\n h1.owners-wide-font, h2.owners-wide-font, h3.owners-wide-font, \n h4.owners-wide-font, h5.owners-wide-font, h6.owners-wide-font {\n text-transform: capitalize; /* Only capitalize first letter of each word */\n }\n \n /* Adobe Fonts specific class */\n .tk-owners-wide {\n font-family: \"owners-wide\", sans-serif;\n }\n 11:T5e2,\n (function(d) {\n var config = {\n kitId: 'wng0qte', // Valid Adobe Fonts kit ID\n scriptTimeout: 3000,\n async: true\n },\n h=d.documentElement,t=setTimeout(function(){\n // If we reach the timeout, mark as inactive and use fallback fonts\n h.className=h.className.replace(/\\bwf-loading\\b/g,\"\")+\" wf-inactive\";\n console.log(\"Adobe Fonts loading timed out - using fallback fonts\");\n },config.scriptTimeout),tk=d.createElement(\"script\"),f=false,s=d.getElementsByTagName(\"script\")[0],a;\n \n h.className+=\" wf-loading\";\n \n tk.src='https://use.typekit.net/'+config.kitId+'.js';\n tk.async=true;\n tk.onload=tk.onreadystatechange=function(){\n a=this.readyState;\n if(f||a\u0026\u0026a!=\"complete\"\u0026\u0026a!=\"loaded\")return;\n f=true;\n clearTimeout(t);\n try{\n Typekit.load(config);\n "])</script><script>self.__next_f.push([1," console.log(\"Adobe Fonts loaded successfully\");\n }catch(e){\n console.error(\"Adobe Fonts could not be loaded:\", e);\n h.className=h.className.replace(/\\bwf-loading\\b/g,\"\")+\" wf-inactive\";\n }\n };\n s.parentNode.insertBefore(tk,s);\n })(document);\n 14:[]\n"])</script><script>self.__next_f.push([1,"0:[\"$\",\"$L2\",null,{\"buildId\":\"static-build-id\",\"assetPrefix\":\"https://d10baati43jr8c.cloudfront.net\",\"urlParts\":[\"\",\"offering\",\"medvector\"],\"initialTree\":[\"\",{\"children\":[\"offering\",{\"children\":[[\"slug\",\"medvector\",\"oc\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],\"initialSeedData\":[\"\",{\"children\":[\"offering\",{\"children\":[[\"slug\",\"medvector\",\"oc\"],{\"children\":[\"__PAGE__\",{},[[\"$L3\",[\"$\",\"div\",null,{\"style\":{\"maxWidth\":\"1198px\",\"margin\":\"0px auto 100px auto\",\"width\":\"100%\",\"padding\":\"0 !important\"},\"data-sentry-component\":\"OfferingComponent\",\"data-sentry-source-file\":\"index.jsx\",\"children\":[\"$\",\"$L4\",null,{\"container\":true,\"data-sentry-element\":\"Grid\",\"data-sentry-source-file\":\"index.jsx\",\"children\":[[\"$\",\"$L4\",null,{\"item\":true,\"xs\":12,\"data-sentry-element\":\"Grid\",\"data-sentry-source-file\":\"index.jsx\",\"children\":[\"$\",\"$5\",null,{\"fallback\":null,\"children\":[[\"$\",\"$L6\",null,{\"moduleIds\":[\"src/components/Offering/index.jsx -\u003e ./HeroSection/HeroSection.server.jsx\"]}],\"$L7\"]}]}],[\"$\",\"$5\",null,{\"fallback\":null,\"children\":[[\"$\",\"$L6\",null,{\"moduleIds\":[\"src/components/Offering/index.jsx -\u003e ./Body.server.jsx\"]}],\"$L8\"]}]]}]}],[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"https://d10baati43jr8c.cloudfront.net/_next/static/css/8c6d8e89db1b876a.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\"}]]],null],null]},[null,[\"$\",\"$L9\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"offering\",\"children\",\"$a\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$Lb\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\"}]],null]},[null,[\"$\",\"$L9\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"offering\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$Lb\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\"}]],null]},[[null,[\"$\",\"html\",null,{\"lang\":\"en\",\"data-sentry-component\":\"RootLayout\",\"data-sentry-source-file\":\"layout.jsx\",\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"meta\",null,{\"charSet\":\"utf-8\",\"data-sentry-element\":\"meta\",\"data-sentry-source-file\":\"layout.jsx\"}],[\"$\",\"meta\",null,{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\",\"data-sentry-element\":\"meta\",\"data-sentry-source-file\":\"layout.jsx\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\",\"data-sentry-element\":\"meta\",\"data-sentry-source-file\":\"layout.jsx\"}],[[\"$\",\"link\",\"0\",{\"rel\":\"shortcut icon\",\"href\":\"https://d10baati43jr8c.cloudfront.net/_next/static/images/favicon.ico\"}],[\"$\",\"link\",\"1\",{\"rel\":\"icon\",\"type\":\"image/png\",\"sizes\":\"16x16\",\"href\":\"https://d10baati43jr8c.cloudfront.net/_next/static/images/favicon-16x16.png\"}],[\"$\",\"link\",\"2\",{\"rel\":\"icon\",\"type\":\"image/png\",\"sizes\":\"32x32\",\"href\":\"https://d10baati43jr8c.cloudfront.net/_next/static/images/favicon-32x32.png\"}],[\"$\",\"link\",\"3\",{\"rel\":\"icon\",\"type\":\"image/png\",\"sizes\":\"192x192\",\"href\":\"https://d10baati43jr8c.cloudfront.net/_next/static/images/android-chrome-192x192.png\"}],[\"$\",\"link\",\"4\",{\"rel\":\"icon\",\"type\":\"image/png\",\"sizes\":\"512x512\",\"href\":\"https://d10baati43jr8c.cloudfront.net/_next/static/images/android-chrome-512x512.png\"}],[\"$\",\"link\",\"5\",{\"rel\":\"apple-touch-icon\",\"href\":\"https://d10baati43jr8c.cloudfront.net/_next/static/images/apple-touch-icon.png\"}]],[\"$\",\"link\",null,{\"rel\":\"preconnect\",\"href\":\"https://fonts.googleapis.com\"}],[\"$\",\"link\",null,{\"rel\":\"preconnect\",\"href\":\"https://fonts.gstatic.com\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.json\"}],[\"$\",\"link\",null,{\"href\":\"https://fonts.googleapis.com/css2?family=IBM+Plex+Sans:wght@400;500;700\u0026display=swap\",\"rel\":\"stylesheet\"}],[\"$\",\"link\",null,{\"rel\":\"stylesheet\",\"href\":\"https://use.typekit.net/wng0qte.css\"}],[\"$\",\"style\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"$c\"}}]]}],[\"$\",\"body\",null,{\"children\":[[\"$\",\"$Ld\",null,{\"data-sentry-element\":\"AppRouterCacheProvider\",\"data-sentry-source-file\":\"layout.jsx\",\"children\":[\"$\",\"$Le\",null,{\"data-sentry-element\":\"ProviderWrapper\",\"data-sentry-source-file\":\"layout.jsx\",\"children\":\"$Lf\"}]}],[\"$\",\"$L10\",null,{\"id\":\"adobe-fonts\",\"strategy\":\"afterInteractive\",\"dangerouslySetInnerHTML\":{\"__html\":\"$11\"},\"data-sentry-element\":\"Script\",\"data-sentry-source-file\":\"layout.jsx\"}],[\"$\",\"noscript\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"\u003ciframe src=\\\"https://www.googletagmanager.com/ns.html?id=GTM-GTM-WFCMXJ4\\\" height=\\\"0\\\" width=\\\"0\\\" style=\\\"display: none; visibility: hidden;\\\" /\u003e\"}}],[\"$\",\"noscript\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"\u003ciframe src=\\\"https://www.googletagmanager.com/ns.html?id=GTM-GTM-KQZCQNP\\\" height=\\\"0\\\" width=\\\"0\\\" style=\\\"display: none; visibility: hidden;\\\" /\u003e\"}}]]}]]}]],null],null],\"couldBeIntercepted\":false,\"initialHead\":[null,\"$L12\"],\"globalErrorComponent\":\"$13\",\"missingSlots\":\"$W14\"}]\n"])</script><script>self.__next_f.push([1,"15:I[3707,[\"5878\",\"static/chunks/9da6db1e-9169ed64657e6864.js\",\"470\",\"static/chunks/668bd8de-6ec84d85db960601.js\",\"1011\",\"static/chunks/1011-41e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"1436\",\"static/chunks/1436-15eb176428e87467.js\",\"4965\",\"static/chunks/4965-f606c91ed72c76bc.js\",\"1460\",\"static/chunks/1460-9f12e0b27390eeec.js\",\"6327\",\"static/chunks/6327-f7792d13e65d135c.js\",\"1276\",\"static/chunks/1276-05b0f8fd32d71634.js\",\"7552\",\"static/chunks/7552-fffb4e0411ff3161.js\",\"7213\",\"static/chunks/7213-8d5a3605c97d38cc.js\",\"2400\",\"static/chunks/2400-7c7bf8747130b0c2.js\",\"2801\",\"static/chunks/2801-e4c70d0bbd17012e.js\",\"8412\",\"static/chunks/8412-12ccaf9f2b652271.js\",\"1622\",\"static/chunks/1622-fe15e70f42096ea6.js\",\"7023\",\"static/chunks/7023-50a07cab75a1f42a.js\",\"3185\",\"static/chunks/app/layout-809685d32afd4b50.js\"],\"SecureCookiesProvider\"]\n16:I[28676,[\"5878\",\"static/chunks/9da6db1e-9169ed64657e6864.js\",\"470\",\"static/chunks/668bd8de-6ec84d85db960601.js\",\"1011\",\"static/chunks/1011-41e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"1436\",\"static/chunks/1436-15eb176428e87467.js\",\"4965\",\"static/chunks/4965-f606c91ed72c76bc.js\",\"1460\",\"static/chunks/1460-9f12e0b27390eeec.js\",\"6327\",\"static/chunks/6327-f7792d13e65d135c.js\",\"1276\",\"static/chunks/1276-05b0f8fd32d71634.js\",\"7552\",\"static/chunks/7552-fffb4e0411ff3161.js\",\"7213\",\"static/chunks/7213-8d5a3605c97d38cc.js\",\"2400\",\"static/chunks/2400-7c7bf8747130b0c2.js\",\"2801\",\"static/chunks/2801-e4c70d0bbd17012e.js\",\"8412\",\"static/chunks/8412-12ccaf9f2b652271.js\",\"1622\",\"static/chunks/1622-fe15e70f42096ea6.js\",\"7023\",\"static/chunks/7023-50a07cab75a1f42a.js\",\"3185\",\"static/chunks/app/layout-809685d32afd4b50.js\"],\"default\"]\n17:I[49912,[\"1011\",\"static/chunks/1011-41"])</script><script>self.__next_f.push([1,"e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"7917\",\"static/chunks/7917-b132173b91dbf639.js\",\"7830\",\"static/chunks/7830-8f7b32e0635d6a81.js\",\"7601\",\"static/chunks/app/error-cc15be88d21aa970.js\"],\"default\"]\n18:I[86212,[\"5878\",\"static/chunks/9da6db1e-9169ed64657e6864.js\",\"1011\",\"static/chunks/1011-41e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"1436\",\"static/chunks/1436-15eb176428e87467.js\",\"4965\",\"static/chunks/4965-f606c91ed72c76bc.js\",\"1460\",\"static/chunks/1460-9f12e0b27390eeec.js\",\"6327\",\"static/chunks/6327-f7792d13e65d135c.js\",\"7213\",\"static/chunks/7213-8d5a3605c97d38cc.js\",\"3215\",\"static/chunks/3215-b420e4ce04b35191.js\",\"1622\",\"static/chunks/1622-fe15e70f42096ea6.js\",\"9160\",\"static/chunks/app/not-found-8e810681f9f14eb6.js\"],\"MainBox\"]\n19:I[86212,[\"5878\",\"static/chunks/9da6db1e-9169ed64657e6864.js\",\"1011\",\"static/chunks/1011-41e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"1436\",\"static/chunks/1436-15eb176428e87467.js\",\"4965\",\"static/chunks/4965-f606c91ed72c76bc.js\",\"1460\",\"static/chunks/1460-9f12e0b27390eeec.js\",\"6327\",\"static/chunks/6327-f7792d13e65d135c.js\",\"7213\",\"static/chunks/7213-8d5a3605c97d38cc.js\",\"3215\",\"static/chunks/3215-b420e4ce04b35191.js\",\"1622\",\"static/chunks/1622-fe15e70f42096ea6.js\",\"9160\",\"static/chunks/app/not-found-8e810681f9f14eb6.js\"],\"Main404Text\"]\n1a:I[53736,[\"5878\",\"static/chunks/9da6db1e-9169ed64657e6864.js\",\"1011\",\"static/chunks/1011-41e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js"])</script><script>self.__next_f.push([1,"\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"1436\",\"static/chunks/1436-15eb176428e87467.js\",\"4965\",\"static/chunks/4965-f606c91ed72c76bc.js\",\"1460\",\"static/chunks/1460-9f12e0b27390eeec.js\",\"6327\",\"static/chunks/6327-f7792d13e65d135c.js\",\"7213\",\"static/chunks/7213-8d5a3605c97d38cc.js\",\"3215\",\"static/chunks/3215-b420e4ce04b35191.js\",\"1622\",\"static/chunks/1622-fe15e70f42096ea6.js\",\"9160\",\"static/chunks/app/not-found-8e810681f9f14eb6.js\"],\"\"]\n1b:I[77213,[\"5878\",\"static/chunks/9da6db1e-9169ed64657e6864.js\",\"1011\",\"static/chunks/1011-41e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"1436\",\"static/chunks/1436-15eb176428e87467.js\",\"4965\",\"static/chunks/4965-f606c91ed72c76bc.js\",\"1460\",\"static/chunks/1460-9f12e0b27390eeec.js\",\"6327\",\"static/chunks/6327-f7792d13e65d135c.js\",\"7213\",\"static/chunks/7213-8d5a3605c97d38cc.js\",\"3215\",\"static/chunks/3215-b420e4ce04b35191.js\",\"1622\",\"static/chunks/1622-fe15e70f42096ea6.js\",\"9160\",\"static/chunks/app/not-found-8e810681f9f14eb6.js\"],\"\"]\n1c:I[38291,[\"5878\",\"static/chunks/9da6db1e-9169ed64657e6864.js\",\"1011\",\"static/chunks/1011-41e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"1436\",\"static/chunks/1436-15eb176428e87467.js\",\"4965\",\"static/chunks/4965-f606c91ed72c76bc.js\",\"1460\",\"static/chunks/1460-9f12e0b27390eeec.js\",\"6327\",\"static/chunks/6327-f7792d13e65d135c.js\",\"7213\",\"static/chunks/7213-8d5a3605c97d38cc.js\",\"3215\",\"static/chunks/3215-b420e4ce04b35191.js\",\"1622\",\"static/chunks/1622-fe15e70f42096ea6.js\",\"9160\",\"static/chunks/app/not-found-8e810681f9f14eb6.js\"],\"default\"]\nf:[\"$\",\"$L15\",null,{\"value\":0.5090277710236359,\"children\":[\"$\",\"$L16\",null,{\"data-sentry-element\":\"LayoutWrapper\",\"data-sentry-source-file\":\"layout.jsx\",\"children\":[\"$\",\"$L9\",null,{\"paralle"])</script><script>self.__next_f.push([1,"lRouterKey\":\"children\",\"segmentPath\":[\"children\"],\"error\":\"$17\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$Lb\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[\"$\",\"$Le\",null,{\"data-sentry-element\":\"ProviderWrapper\",\"data-sentry-component\":\"NotFound\",\"data-sentry-source-file\":\"not-found.jsx\",\"children\":[\"$\",\"$L4\",null,{\"sx\":{\"my\":{\"xs\":\"200px\"},\"px\":{\"xs\":2,\"lg\":0}},\"data-sentry-element\":\"Grid\",\"data-sentry-source-file\":\"not-found.jsx\",\"children\":[\"$\",\"$L18\",null,{\"data-sentry-element\":\"MainBox\",\"data-sentry-source-file\":\"not-found.jsx\",\"children\":[[\"$\",\"$L19\",null,{\"data-sentry-element\":\"Main404Text\",\"data-sentry-source-file\":\"not-found.jsx\",\"children\":\"404\"}],[\"$\",\"$L1a\",null,{\"variant\":\"p1Medium\",\"align\":\"center\",\"sx\":{\"maxWidth\":\"344px\"},\"mb\":2,\"data-sentry-element\":\"Typography\",\"data-sentry-source-file\":\"not-found.jsx\",\"children\":\"This page you're looking for doesn't exist or has been moved. Let's go back home.\"}],[\"$\",\"$L1b\",null,{\"href\":\"/\",\"data-sentry-element\":\"Link\",\"data-sentry-source-file\":\"not-found.jsx\",\"children\":[\"$\",\"$L1c\",null,{\"variant\":\"contained\",\"sx\":{\"height\":\"48px\",\"width\":\"327px\"},\"data-sentry-element\":\"Button\",\"data-sentry-source-file\":\"not-found.jsx\",\"children\":\"Go Back Home\"}]}]]}]}]}],\"notFoundStyles\":[]}]}]}]\n"])</script><script>self.__next_f.push([1,"1d:I[24502,[\"5878\",\"static/chunks/9da6db1e-9169ed64657e6864.js\",\"470\",\"static/chunks/668bd8de-6ec84d85db960601.js\",\"8760\",\"static/chunks/c473e9eb-b152521f8f339159.js\",\"6631\",\"static/chunks/8c82368a-d72c5658ab9f6a28.js\",\"161\",\"static/chunks/0b216c82-a199d56bfdf3cb5a.js\",\"5042\",\"static/chunks/2b0f660e-4b9f1787362c5b34.js\",\"4358\",\"static/chunks/bc9e92e6-c3262bc18bd04989.js\",\"4533\",\"static/chunks/d441faa4-d842044025885ba0.js\",\"2544\",\"static/chunks/2cea0ef4-1e49e852888961e4.js\",\"1011\",\"static/chunks/1011-41e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"1436\",\"static/chunks/1436-15eb176428e87467.js\",\"4965\",\"static/chunks/4965-f606c91ed72c76bc.js\",\"1460\",\"static/chunks/1460-9f12e0b27390eeec.js\",\"7917\",\"static/chunks/7917-b132173b91dbf639.js\",\"3928\",\"static/chunks/3928-7a4e28f8d12ef4d2.js\",\"1276\",\"static/chunks/1276-05b0f8fd32d71634.js\",\"7552\",\"static/chunks/7552-fffb4e0411ff3161.js\",\"2802\",\"static/chunks/2802-99eef326aadd79e5.js\",\"895\",\"static/chunks/895-392d5ace72c822d2.js\",\"8386\",\"static/chunks/8386-d0882ee23ba2316e.js\",\"5564\",\"static/chunks/5564-342c92fdf012bdd8.js\",\"6916\",\"static/chunks/6916-8c240cbdfa162fcc.js\",\"2400\",\"static/chunks/2400-7c7bf8747130b0c2.js\",\"2615\",\"static/chunks/2615-8cdfb3159fa66a17.js\",\"1338\",\"static/chunks/1338-3f5c3667f246a81d.js\",\"6113\",\"static/chunks/6113-df22ad27d8ec74e5.js\",\"754\",\"static/chunks/754-c0d142adc8d77a4d.js\",\"694\",\"static/chunks/694-d3138f0894c7dc7a.js\",\"5459\",\"static/chunks/5459-511213434c14b424.js\",\"4714\",\"static/chunks/4714-4830fb73fed502a1.js\",\"952\",\"static/chunks/app/offering/%5B%5B...slug%5D%5D/page-d393148abba33621.js\"],\"HydrationBoundary\"]\n1e:I[78278,[\"5878\",\"static/chunks/9da6db1e-9169ed64657e6864.js\",\"470\",\"static/chunks/668bd8de-6ec84d85db960601.js\",\"8760\",\"static/chunks/c473e9eb-b152521f8f339159.js\",\"6631\",\"static/chunks/8c82368a-d72c5658ab9f6a28.js\",\"161\",\"static/chunks/0b216c82-a199d56bfdf3cb5a.js\",\"504"])</script><script>self.__next_f.push([1,"2\",\"static/chunks/2b0f660e-4b9f1787362c5b34.js\",\"4358\",\"static/chunks/bc9e92e6-c3262bc18bd04989.js\",\"4533\",\"static/chunks/d441faa4-d842044025885ba0.js\",\"2544\",\"static/chunks/2cea0ef4-1e49e852888961e4.js\",\"1011\",\"static/chunks/1011-41e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"1436\",\"static/chunks/1436-15eb176428e87467.js\",\"4965\",\"static/chunks/4965-f606c91ed72c76bc.js\",\"1460\",\"static/chunks/1460-9f12e0b27390eeec.js\",\"7917\",\"static/chunks/7917-b132173b91dbf639.js\",\"3928\",\"static/chunks/3928-7a4e28f8d12ef4d2.js\",\"1276\",\"static/chunks/1276-05b0f8fd32d71634.js\",\"7552\",\"static/chunks/7552-fffb4e0411ff3161.js\",\"2802\",\"static/chunks/2802-99eef326aadd79e5.js\",\"895\",\"static/chunks/895-392d5ace72c822d2.js\",\"8386\",\"static/chunks/8386-d0882ee23ba2316e.js\",\"5564\",\"static/chunks/5564-342c92fdf012bdd8.js\",\"6916\",\"static/chunks/6916-8c240cbdfa162fcc.js\",\"2400\",\"static/chunks/2400-7c7bf8747130b0c2.js\",\"2615\",\"static/chunks/2615-8cdfb3159fa66a17.js\",\"1338\",\"static/chunks/1338-3f5c3667f246a81d.js\",\"6113\",\"static/chunks/6113-df22ad27d8ec74e5.js\",\"754\",\"static/chunks/754-c0d142adc8d77a4d.js\",\"694\",\"static/chunks/694-d3138f0894c7dc7a.js\",\"5459\",\"static/chunks/5459-511213434c14b424.js\",\"4714\",\"static/chunks/4714-4830fb73fed502a1.js\",\"952\",\"static/chunks/app/offering/%5B%5B...slug%5D%5D/page-d393148abba33621.js\"],\"default\"]\n1f:T258a,"])</script><script>self.__next_f.push([1,"\u003ch1 dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/h1\u003e\u003ctable align=\"left\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd class=\"fr-thick\" style=\"text-align: right; width: 48.4324%; vertical-align: middle;\" valign=\"top\" width=\"31%\"\u003e\u003ch4\u003e\u003cstrong\u003eCompany\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd class=\"fr-thick\" style=\"width: 3.2433%; text-align: center;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd class=\"fr-thick\" style=\"text-align: left; width: 48.3244%;\" valign=\"top\" width=\"68%\"\u003e\u003ch4\u003eMedVector Corp.\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"text-align: right; width: 48.4324%; vertical-align: middle;\" valign=\"top\" width=\"31%\"\u003e\u003ch4\u003e\u003cstrong\u003eCorporate Address\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"width: 3.2433%; text-align: center;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"text-align: left; width: 48.3244%;\" valign=\"top\" width=\"68%\"\u003e\u003ch4\u003e898 N. Pacific Coast Highway, El Segundo, CA 90245\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"vertical-align: middle; width: 48.4324%;\"\u003e\u003ch4 style=\"text-align: right;\"\u003e\u003cstrong\u003eOffering Minimum\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"width: 3.2433%;\"\u003e\u003cdiv style=\"text-align: center;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003c/div\u003e\u003c/td\u003e\u003ctd\u003e\u003ch4\u003e$15,000.00\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd class=\"fr-thick\" style=\"text-align: right; width: 48.4324%; vertical-align: middle;\" valign=\"top\" width=\"31%\"\u003e\u003ch4\u003e\u003cstrong\u003eOffering Maximum\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd class=\"fr-thick\" style=\"width: 3.2433%; text-align: center;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd class=\"fr-thick\" style=\"text-align: left; width: 48.3244%; vertical-align: middle;\" valign=\"top\" width=\"68%\"\u003e\u003ch4\u003e$618,000.00\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd class=\"fr-thick\" style=\"text-align: right; width: 48.4324%; vertical-align: middle;\" valign=\"top\" width=\"31%\"\u003e\u003ch4\u003e\u003cstrong\u003eMinimum Investment Amount\u003c/strong\u003e\u003c/h4\u003e\u003ch4\u003e\u003cstrong\u003e(per investor)\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd class=\"fr-thick\" style=\"width: 3.2433%; text-align: center;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd class=\"fr-thick\" style=\"text-align: left; width: 48.3244%; vertical-align: middle;\" valign=\"top\" width=\"68%\"\u003e\u003ch4\u003e$500.00\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/table\u003e\u003cp style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003ch4 style=\"text-align: center;\"\u003eTerms\u003c/h4\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003ctable align=\"left\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd style=\"width: 48.2162%; text-align: right;\"\u003e\u003ch4\u003e\u003cstrong\u003eOffering Type\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"width: 3.2433%; text-align: center;\"\u003e:\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"width: 48.2681%;\" valign=\"top\" width=\"68%\"\u003e\u003ch4\u003eConvertible Promissory Notes\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"text-align: right; width: 48.2162%;\"\u003e\u003ch4\u003e\u003cstrong\u003eType of Equity Converted Into\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"text-align: center; width: 3.2433%;\"\u003e:\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"width: 48.2681%;\"\u003e\u003ch4\u003eCommon Stock\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"text-align: right; width: 48.2162%;\"\u003e\u003ch4\u003e\u003cstrong\u003eConversion Trigger\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"text-align: center; width: 3.2433%;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"width: 48.2681%;\"\u003e\u003ch4\u003e$3,000,000.00\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"text-align: right; width: 48.2162%;\"\u003e\u003ch4\u003e\u003cstrong\u003eMaturity Date\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"text-align: center; width: 3.2433%;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"width: 48.2681%;\"\u003e\u003ch4\u003eMay 01, 2026\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"text-align: right; width: 48.2162%;\"\u003e\u003ch4\u003e\u003cstrong\u003eValuation Cap\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"text-align: center; width: 3.2433%;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"width: 48.2681%;\"\u003e\u003ch4\u003e$25,000,000.00\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"text-align: right; width: 48.2162%;\"\u003e\u003ch4\u003e\u003cstrong\u003eDiscount Rate\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"text-align: center; width: 3.2433%;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"width: 48.2681%;\"\u003e\u003ch4\u003e12.0%\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"text-align: right; width: 48.2162%;\"\u003e\u003ch4\u003e\u003cstrong\u003eAnnual Interest Rate\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"text-align: center; width: 3.2433%;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"width: 48.2681%;\"\u003e\u003ch4\u003e4.85%\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/table\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\"\u003e\u003cspan style=\"font-size: 18px;\"\u003e\u003cstrong\u003eWhat is a Convertible Note?\u003c/strong\u003e\u003c/span\u003e\u003c/p\u003e\u003cp dir=\"ltr\"\u003e\u003cspan style=\"font-size: 18px;\"\u003eA convertible note offers you the right to receive Common Stock in MedVector Corp.. The amount of \u003cspan style=\"font-size: 18px;\"\u003eCommon Stock\u003c/span\u003e you will receive in the future will be determined at the next equity round in which the Company raises at least $3,000,000.00 in a qualified equity financing. The highest conversion price per security is set based on a $25,000,000.00 \u0026nbsp;Valuation Cap or if less, then you will receive a 12.0% discount on the price the new investors are paying. \u0026nbsp;You also receive 4.85% interest per year added to your investment. \u0026nbsp;When the maturity date is reached, if the note has not converted then you are entitled to receive Common Stock equal to your investment and interest back at a price per security determined by dividing the Valuation Cap by the aggregate number of outstanding equity securities of the Company as of immediately prior (on a fully diluted basis).\u003c/span\u003e\u003c/p\u003e\u003cp dir=\"ltr\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003e*Annual Interest Rate subject to adjustment of 10% bonus for StartEngine shareholders. See 10% Bonus below.\u003c/em\u003e\u003c/p\u003e\n\u003cp style=\"text-align:center;\"\u003e\u003cstrong\u003eVoting Rights of Securities Sold in this Offering\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eVoting Proxy. Should the convertible promissory notes sold in this offering convert into shares of Common Stock, each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.\u003c/p\u003e\n\u003cp style=\"text-align:center;\"\u003e\u003cstrong\u003e\u003cins\u003eInvestment Incentives and Bonuses*\u003c/ins\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLoyalty Bonus | 20% Bonus Interest\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAs you are an existing investor in MedVector, you are eligible for additional bonus interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTime-Based Investment Incentives\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEarly Bird\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eInvest within the first two weeks and receive 10% bonus interest.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus interest from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed. Crowdfunding investments made through a self-directed IRA cannot receive perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those perks because they would be receiving a benefit from their IRA account.\u003c/em\u003e\u003c/p\u003e\n\u003cp style=\"text-align:center;\"\u003e\u003cstrong\u003eThe 10% StartEngine Venture Club\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMedVector Corp. will offer a 10% additional bonus interest for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding, Inc. Venture Club bonus.\u003c/p\u003e\n\u003cp\u003eEligible StartEngine convertible note holders will receive a 10% increase in the annual interest rate on Convertible Promissory Notes in this Offering. This means your annual interest rate will be 5.335% instead of 4.85%.\u003c/p\u003e\n\u003cp\u003eThis 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.\u003c/p\u003e\n\u003cp\u003eEligible investors will also receive the Venture Club Bonus and the Loyalty Bonus in addition to the Early Bird bonus.\u003c/p\u003e\n"])</script><script>self.__next_f.push([1,"20:Tf59,"])</script><script>self.__next_f.push([1,"\u003cp\u003e\u003cem\u003e*Annual Interest Rate subject to adjustment of 10% bonus for StartEngine shareholders. See 10% Bonus below.\u003c/em\u003e\u003c/p\u003e\n\u003cp style=\"text-align:center;\"\u003e\u003cstrong\u003eVoting Rights of Securities Sold in this Offering\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eVoting Proxy. Should the convertible promissory notes sold in this offering convert into shares of Common Stock, each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.\u003c/p\u003e\n\u003cp style=\"text-align:center;\"\u003e\u003cstrong\u003e\u003cins\u003eInvestment Incentives and Bonuses*\u003c/ins\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLoyalty Bonus | 20% Bonus Interest\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAs you are an existing investor in MedVector, you are eligible for additional bonus interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTime-Based Investment Incentives\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEarly Bird\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eInvest within the first two weeks and receive 10% bonus interest.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus interest from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed. Crowdfunding investments made through a self-directed IRA cannot receive perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those perks because they would be receiving a benefit from their IRA account.\u003c/em\u003e\u003c/p\u003e\n\u003cp style=\"text-align:center;\"\u003e\u003cstrong\u003eThe 10% StartEngine Venture Club\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMedVector Corp. will offer a 10% additional bonus interest for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding, Inc. Venture Club bonus.\u003c/p\u003e\n\u003cp\u003eEligible StartEngine convertible note holders will receive a 10% increase in the annual interest rate on Convertible Promissory Notes in this Offering. This means your annual interest rate will be 5.335% instead of 4.85%.\u003c/p\u003e\n\u003cp\u003eThis 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.\u003c/p\u003e\n\u003cp\u003eEligible investors will also receive the Venture Club Bonus and the Loyalty Bonus in addition to the Early Bird bonus.\u003c/p\u003e\n"])</script><script>self.__next_f.push([1,"7:[\"$\",\"$L1d\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"state\":{\"data\":{\"id\":\"d50479f1-8824-4cea-a2ce-782675405bb9\",\"slug\":\"medvector\",\"content\":\"A clinical trial could save your life… \",\"coverDesktopUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/images/startup_cover/desktop_MedVector_Cover_Image_V.1.jpg\",\"elevatorPitch\":\"MedVector utilizes telemedicine for clinical trials. Now patients can benefit from advanced medicine as a treatment option from their trusted doctor’s office. Our FDA and HIPAA-compliant platform unlocks access to potentially millions of patients, driving rapid clinical trial enrollment, and bringing lifesaving medications to those who need it, faster and more affordably. \\n \\nMedVector is currently operational, but pre-revenue.\"},\"dataUpdateCount\":1,\"dataUpdatedAt\":1752925656721,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"offeringHeroSectionData\"],\"queryHash\":\"[\\\"offeringHeroSectionData\\\"]\"}]},\"data-sentry-element\":\"HydrationBoundary\",\"data-sentry-component\":\"HeroSectionServerComponent\",\"data-sentry-source-file\":\"HeroSection.server.jsx\",\"children\":[\"$\",\"$L4\",null,{\"container\":true,\"sx\":{\"marginBottom\":{\"md\":10}},\"children\":[\"$\",\"$L4\",null,{\"item\":true,\"sx\":{\"margin\":{\"xs\":\"0 auto\",\"md\":0}},\"children\":[\"$\",\"$L1e\",null,{\"offeringDataServer\":{\"id\":\"d50479f1-8824-4cea-a2ce-782675405bb9\",\"primaryId\":\"65e9de403f97f4590acb81b7\",\"externalId\":\"65e9de403f97f4590acb81b7\",\"entitySource\":\"PRIMARY\",\"slug\":\"medvector\",\"name\":\"MedVector\",\"content\":\"A clinical trial could save your life… \",\"categories\":[{\"id\":\"2b2c41ed-f782-41bf-91e5-67096a10c8e3\",\"name\":\"Health Tech\",\"label\":\"health-tech\",\"imageUrl\":\"https://d2j6gq8tvnyhoe.cloudfront.net/mobile/discover/0689c66e-f0b0-447b-860c-b0b188f531d8.png\"}],\"regulationType\":\"Reg CF\",\"offeringType\":\"convertible_note\",\"coverDesktopUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/images/startup_cover/desktop_MedVector_Cover_Image_V.1.jpg\",\"coverTombstoneUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/images/startup_cover/tombstone_MedVector_Cover_Image_V.1.jpg\",\"logoUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/images/startup_image/profile_medlogo.jpg\",\"videoUrl\":\"https://youtu.be/r8MN5CoACM0\",\"status\":\"closed\",\"maximumFundingAmount\":\"618000.00 USD\",\"previousRaiseTotal\":\"0.00 USD\",\"previousCrowdfundedRaiseTotal\":\"874284.75 USD\",\"previousRaiseInvestorCount\":0,\"valuation\":\"22000000.00 USD\",\"valuationCap\":\"25000000.00 USD\",\"amountRaised\":\"118732.51 USD\",\"endDate\":\"2024-08-20T06:59:59.999Z\",\"startDate\":\"2024-05-21T17:58:58.985Z\",\"showFundingGoal\":true,\"fundingGoal\":\"15000.00 USD\",\"minimumNumberOfSharesOffered\":0,\"maximumNumberOfSharesOffered\":0,\"minimumInvestmentAmount\":\"500.00 USD\",\"maximumInvestmentAmount\":\"618000.00 USD\",\"elevatorPitch\":\"MedVector utilizes telemedicine for clinical trials. Now patients can benefit from advanced medicine as a treatment option from their trusted doctor’s office. Our FDA and HIPAA-compliant platform unlocks access to potentially millions of patients, driving rapid clinical trial enrollment, and bringing lifesaving medications to those who need it, faster and more affordably. \\n \\nMedVector is currently operational, but pre-revenue.\",\"numberOfContributors\":57,\"numberOfInvestors\":57,\"showPercentCompleted\":true,\"website\":\"medvector.com\",\"terms\":\"$1f\",\"team\":[{\"id\":\"0106ad30-365d-4cd2-88a8-0f60ea77f740\",\"fullName\":\"Dr. Dennis Patterson\",\"title\":\"Hospital Relations, Board Member \u0026 Co-Founder\",\"bio\":\"\u003cp\u003eDr. Patterson brings a wealth of knowledge from hospital management roles at Ernst \u0026amp; Young (UK) and was a founder of Wellspring Partners. He leads MedVector's hospital relationships.\u003c/p\u003e\\r\\n\",\"position\":3,\"twitterUrl\":\"\",\"linkedinUrl\":\"https://www.linkedin.com/in/dennis-pattterson-b48b455/\",\"facebookUrl\":\"\",\"founder\":true,\"profileImageUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/founders/images/profile_image/founder_dennismedv.jpg\"},{\"id\":\"18a4dc58-7af5-42d1-b847-0e4a16012600\",\"fullName\":\"Ian Leaman\",\"title\":\"Board Member, Fractional CFO\",\"bio\":\"\u003cp\u003eA Deloitte-trained Chartered Accountant with Board and Senior Finance Executive experience. Over 50 completed M\u0026amp;A's. Senior finance positions both in US and Internationally. FINRA registered Investment Banker (S.79).\u003c/p\u003e\\r\\n\u003cp\u003eIn addition to working approximately 7 hours per week for MedVector, Ian also splits his time working for other companies: Arkeytyp Holdings Ltd. (CFO), ~2 hours per week; Curriqunet (CFO), ~9 hours per week; AIDA Intelligent Solutions (fractional CFO), ~4 hours per week; Marula Capital LLC (Managing Director), ~3 hours per week; Legion Creative (Director), ~2 hours per week; BrandInc (fractional CFO), ~3 hours per week, and Duke \u0026amp; Leaman LLC ( Owner), ~10 hours per week.\u003c/p\u003e\\r\\n\",\"position\":1,\"twitterUrl\":\"\",\"linkedinUrl\":\"https://www.linkedin.com/in/ianleaman/\",\"facebookUrl\":\"\",\"founder\":false,\"profileImageUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/founders/images/profile_image/founder_ianmedmask_group.jpg\"},{\"id\":\"4fe8005d-1bca-4692-8e37-64e794e7c4f3\",\"fullName\":\"Scott Stout\",\"title\":\"CEO, Board Member \u0026 Founder\",\"bio\":\"\u003cp\u003eAn established healthcare innovator, named one of the Most Influential Healthcare Leaders in 2021 and recognized by Marquis’ Who’s Who in 2024, Scott brings financial expertise from Morgan Stanley where he aided several startups on their capital structures and go-to-market strategies. He excels at strategic direction, team building, and securing capital.\u003c/p\u003e\\r\\n\",\"position\":0,\"twitterUrl\":\"\",\"linkedinUrl\":\"https://www.linkedin.com/in/scott-stout-01992653/\",\"facebookUrl\":\"\",\"founder\":true,\"profileImageUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/founders/images/profile_image/founder_scottmedmask_group.jpg\"},{\"id\":\"1f13790a-8759-4201-a023-11dd077d7f90\",\"fullName\":\"Craig Lipset\",\"title\":\"Board Member\",\"bio\":\"\u003cp\u003eCraig Lipset leads at the forefront of innovation in clinical research and medicine development. He is an advisor to technology and biopharmaceutical companies, leading universities, and the venture community and was the Head of Clinical Innovation and Venture Partner at Pfizer. He continues to be one of the leading industry voices of decentralized clinical trials and innovation.\u003c/p\u003e\\r\\n\",\"position\":4,\"twitterUrl\":\"\",\"linkedinUrl\":\"https://www.linkedin.com/in/lipset/\",\"facebookUrl\":\"\",\"founder\":false,\"profileImageUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/founders/images/profile_image/founder_craigmedv.jpg\"},{\"id\":\"fc6ec87a-515c-46e8-9e53-d3e045cd6078\",\"fullName\":\"Ted Barduson\",\"title\":\"Chief Operating Officer, Board Member \u0026 Co-Founder \",\"bio\":\"\u003cp\u003eWith over 35 years in healthcare, Ted is an expert in scaling operations, revenue cycle management, and mergers \u0026amp; acquisitions. His passion lies in accelerating access to life-changing treatments.\u003c/p\u003e\\r\\n\",\"position\":2,\"twitterUrl\":\"\",\"linkedinUrl\":\"https://www.linkedin.com/in/tedbarduson/\",\"facebookUrl\":\"\",\"founder\":true,\"profileImageUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/founders/images/profile_image/founder_tedmedmask_group.jpg\"}],\"debtInterestRate\":4.85,\"debtMaturityDate\":\"2026-05-01T00:00:00.000Z\",\"discountRate\":12,\"investorFeeRate\":3.5,\"investorFeeCap\":\"700.00 USD\",\"seFeeRate\":9,\"seIntlFeeRate\":9,\"ccFeeRate\":0,\"securitySymbol\":\"MVCNNP\",\"offeringCircularUrl\":\"https://www.sec.gov/Archives/edgar/data/1820902/000166516024000884/0001665160-24-000884-index.htm\",\"secUrl\":\"https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001820902\u0026owner=exclude\u0026action=getcompany\u0026Find=Search\",\"signToTradeDisclosureUrl\":\"https://www.startengine.com/signed-to-trade-disclosure\",\"offeringDetailsUrl\":\"https://startenginebetadev.s3.amazonaws.com/production/startups/65e9de403f97f4590acb81b7/documents/offering_details/edgar_1715881433_offering_memorandum.pdf\",\"issuerTitle\":\"CEO \u0026 Co-Founder\",\"issuerLocation\":\"CA\",\"stateIncorporated\":\"DE\",\"dateOfLaunch\":\"2024-05-21T17:58:58.985Z\",\"approvedAt\":\"2024-05-21T17:58:58.985Z\",\"issuerName\":\"MedVector Corp.\",\"addressLine1\":\"898 N. Pacific Coast Highway\",\"city\":\"El Segundo\",\"state\":\"CA\",\"zipcode\":\"90245\",\"numberOfHoursLeft\":-7996,\"allowCreditCards\":true,\"allowCryptoPayments\":false,\"company\":{\"id\":\"ec7fbf90-0883-4553-bd21-90abd367e09e\",\"legalName\":\"MedVector Corp.\",\"externalId\":\"65e9de443f97f401e15763f4\"},\"startengineCompany\":{\"id\":\"e7bc5349-4ea1-4ea3-845a-55de3a9134b3\",\"companyName\":\"StartEngine Capital, LLC\"},\"useAngelInvestmentSvc\":false,\"seBrokerDealer\":false,\"seSellingBrokerDealer\":false,\"escrowProvider\":{\"id\":\"79667ef6-9e1d-4549-8572-88d270e96abd\",\"name\":\"BRYN_MAWR\",\"label\":\"Bryn Mawr\",\"primaryEscrowProviderId\":\"617b62495aaa397a9fd44b75\"},\"escrowProviderStatus\":\"OPEN\",\"showSameRaiseTotals\":false,\"showTombstoneRaiseBar\":false,\"seBonusApplicable\":true,\"hideHighlights\":false,\"teamSectionDisabled\":false,\"commentsEnabled\":true,\"irregularUseOfProceeds\":\"The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Any expense labeled “Travel and Entertainment”. \",\"excludedStates\":[],\"accountHolderUserId\":\"65e9dd857254bf785dceb032\",\"securityName\":\"Common Stock\",\"valuationDetails\":\"Example - We have not undertaken any efforts to produce a valuation of the Company. The price of the shares merely reflects the opinion of the Company as to what would be fair market value.\",\"anticipatedAmount\":\"$$1,000,000+\",\"internationalInvestorsAllowed\":true,\"cashAndCashEquivalentsPriorYear\":\"430542.00 USD\",\"cashAndCashEquivalentsRecentYear\":\"64386.00 USD\",\"accountsReceivablePriorYear\":\"0.00 USD\",\"accountsReceivableRecentYear\":\"0.00 USD\",\"shortTermDebtPriorYear\":\"360140.00 USD\",\"shortTermDebtRecentYear\":\"392239.00 USD\",\"longTermDebtPriorYear\":\"0.00 USD\",\"longTermDebtRecentYear\":\"0.00 USD\",\"revenueAndSalesPriorYear\":\"0.00 USD\",\"revenueAndSalesRecentYear\":\"0.00 USD\",\"costOfGoodsSoldPriorYear\":\"0.00 USD\",\"costOfGoodsSoldRecentYear\":\"0.00 USD\",\"taxesPaidPriorYear\":\"0.00 USD\",\"taxesPaidRecentYear\":\"0.00 USD\",\"netIncomePriorYear\":\"-653737.00 USD\",\"netIncomeRecentYear\":\"-704633.00 USD\",\"totalAssetsPriorYear\":\"759063.00 USD\",\"totalAssetsRecentYear\":\"411528.00 USD\",\"conversion\":3000000,\"investmentAccountRequiredToComment\":true,\"offeringTermsDescription\":\"A convertible note offers you the right to receive Common Stock in MedVector. The amount of Common Stock you will receive in the future will be determined at the next equity round in which the Company raises at least $3,000,000.00 in a qualified equity financing. The highest conversion price per security is set based on a $25,000,000.00 Valuation Cap or if less, then you will receive a 12.00% discount on the price the new investors are paying. You also receive 4.85% interest per year added to your investment. When the maturity date is reached, if the note has not converted then you are entitled to receive Common Stock equal to your investment and interest back at a price per security determined by dividing the Valuation Cap by the aggregate number of outstanding equity securities of the Company as of immediately prior (on a fully diluted basis).\",\"perksAndOtherMaterialInformation\":\"$20\",\"convertibleName\":\"Common Stock\",\"internalAmountRaised\":\"118732.51 USD\",\"investorMatchedOffering\":false,\"hasCampaignPage\":true,\"tierLevel\":\"TIER_2\",\"restricted\":false,\"rewardsCap\":null,\"rolloverDetails\":[],\"lockedOnWaitlist\":false,\"partners\":[],\"retirementFundsOnly\":false,\"ceo\":\"Scott Stout\",\"issuerAddress\":\"898 N. Pacific Coast Highway, El Segundo, CA 90245\",\"hqLocation\":\"El Segundo, CA\",\"isOverMax\":false},\"content\":\"A clinical trial could save your life… \",\"elevatorPitch\":\"MedVector utilizes telemedicine for clinical trials. Now patients can benefit from advanced medicine as a treatment option from their trusted doctor’s office. Our FDA and HIPAA-compliant platform unlocks access to potentially millions of patients, driving rapid clinical trial enrollment, and bringing lifesaving medications to those who need it, faster and more affordably. \\n \\nMedVector is currently operational, but pre-revenue.\",\"coverDesktopUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/images/startup_cover/desktop_MedVector_Cover_Image_V.1.jpg\"}]}]}]}]\n"])</script><script>self.__next_f.push([1,"12:[[\"$\",\"meta\",\"0\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}],[\"$\",\"meta\",\"1\",{\"charSet\":\"utf-8\"}],[\"$\",\"title\",\"2\",{\"children\":\"MedVector (Reg CF) | StartEngine\"}],[\"$\",\"meta\",\"3\",{\"name\":\"description\",\"content\":\"MedVector: A clinical trial could save your life… \"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"a,clinical,trial,could,save,your,life\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://www.startengine.com/offering/medvector\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"MedVector (Reg CF) | StartEngine\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"MedVector: A clinical trial could save your life… \"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://www.startengine.com/offering/medvector\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"StartEngine\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/images/startup_cover/desktop_MedVector_Cover_Image_V.1.jpg\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:alt\",\"content\":\"MedVector | StartEngine\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:width\",\"content\":\"1225\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:height\",\"content\":\"630\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:image:type\",\"content\":\"image/jpg\"}],[\"$\",\"meta\",\"18\",{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary_large_image\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:title\",\"content\":\"MedVector (Reg CF) | StartEngine\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:description\",\"content\":\"MedVector: A clinical trial could save your life… \"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:image\",\"content\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/images/startup_cover/desktop_MedVector_Cover_Image_V.1.jpg\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image:alt\",\"content\":\"MedVector | StartEngine\"}],[\"$\",\"meta\",\"24\",{\"name\":\"twitter:image:width\",\"content\":\"1225\"}],[\"$\",\"meta\",\"25\",{\"name\":\"twitter:image:height\",\"content\":\"630\"}],[\"$\",\"meta\",\"26\",{\"name\":\"twitter:image:type\",\"content\":\"image/jpg\"}]]\n"])</script><script>self.__next_f.push([1,"3:null\n"])</script><script>self.__next_f.push([1,"21:I[17893,[\"5878\",\"static/chunks/9da6db1e-9169ed64657e6864.js\",\"470\",\"static/chunks/668bd8de-6ec84d85db960601.js\",\"8760\",\"static/chunks/c473e9eb-b152521f8f339159.js\",\"6631\",\"static/chunks/8c82368a-d72c5658ab9f6a28.js\",\"161\",\"static/chunks/0b216c82-a199d56bfdf3cb5a.js\",\"5042\",\"static/chunks/2b0f660e-4b9f1787362c5b34.js\",\"4358\",\"static/chunks/bc9e92e6-c3262bc18bd04989.js\",\"4533\",\"static/chunks/d441faa4-d842044025885ba0.js\",\"2544\",\"static/chunks/2cea0ef4-1e49e852888961e4.js\",\"1011\",\"static/chunks/1011-41e06f025ea7984c.js\",\"8819\",\"static/chunks/8819-ba545f32a4c9557e.js\",\"3027\",\"static/chunks/3027-b1df9a7cdf4a090b.js\",\"8291\",\"static/chunks/8291-4172a7e59f3a2c0c.js\",\"6100\",\"static/chunks/6100-4fd3e2a0b029472e.js\",\"1436\",\"static/chunks/1436-15eb176428e87467.js\",\"4965\",\"static/chunks/4965-f606c91ed72c76bc.js\",\"1460\",\"static/chunks/1460-9f12e0b27390eeec.js\",\"7917\",\"static/chunks/7917-b132173b91dbf639.js\",\"3928\",\"static/chunks/3928-7a4e28f8d12ef4d2.js\",\"1276\",\"static/chunks/1276-05b0f8fd32d71634.js\",\"7552\",\"static/chunks/7552-fffb4e0411ff3161.js\",\"2802\",\"static/chunks/2802-99eef326aadd79e5.js\",\"895\",\"static/chunks/895-392d5ace72c822d2.js\",\"8386\",\"static/chunks/8386-d0882ee23ba2316e.js\",\"5564\",\"static/chunks/5564-342c92fdf012bdd8.js\",\"6916\",\"static/chunks/6916-8c240cbdfa162fcc.js\",\"2400\",\"static/chunks/2400-7c7bf8747130b0c2.js\",\"2615\",\"static/chunks/2615-8cdfb3159fa66a17.js\",\"1338\",\"static/chunks/1338-3f5c3667f246a81d.js\",\"6113\",\"static/chunks/6113-df22ad27d8ec74e5.js\",\"754\",\"static/chunks/754-c0d142adc8d77a4d.js\",\"694\",\"static/chunks/694-d3138f0894c7dc7a.js\",\"5459\",\"static/chunks/5459-511213434c14b424.js\",\"4714\",\"static/chunks/4714-4830fb73fed502a1.js\",\"952\",\"static/chunks/app/offering/%5B%5B...slug%5D%5D/page-d393148abba33621.js\"],\"default\"]\n22:T258a,"])</script><script>self.__next_f.push([1,"\u003ch1 dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/h1\u003e\u003ctable align=\"left\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd class=\"fr-thick\" style=\"text-align: right; width: 48.4324%; vertical-align: middle;\" valign=\"top\" width=\"31%\"\u003e\u003ch4\u003e\u003cstrong\u003eCompany\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd class=\"fr-thick\" style=\"width: 3.2433%; text-align: center;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd class=\"fr-thick\" style=\"text-align: left; width: 48.3244%;\" valign=\"top\" width=\"68%\"\u003e\u003ch4\u003eMedVector Corp.\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"text-align: right; width: 48.4324%; vertical-align: middle;\" valign=\"top\" width=\"31%\"\u003e\u003ch4\u003e\u003cstrong\u003eCorporate Address\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"width: 3.2433%; text-align: center;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"text-align: left; width: 48.3244%;\" valign=\"top\" width=\"68%\"\u003e\u003ch4\u003e898 N. Pacific Coast Highway, El Segundo, CA 90245\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"vertical-align: middle; width: 48.4324%;\"\u003e\u003ch4 style=\"text-align: right;\"\u003e\u003cstrong\u003eOffering Minimum\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"width: 3.2433%;\"\u003e\u003cdiv style=\"text-align: center;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003c/div\u003e\u003c/td\u003e\u003ctd\u003e\u003ch4\u003e$15,000.00\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd class=\"fr-thick\" style=\"text-align: right; width: 48.4324%; vertical-align: middle;\" valign=\"top\" width=\"31%\"\u003e\u003ch4\u003e\u003cstrong\u003eOffering Maximum\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd class=\"fr-thick\" style=\"width: 3.2433%; text-align: center;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd class=\"fr-thick\" style=\"text-align: left; width: 48.3244%; vertical-align: middle;\" valign=\"top\" width=\"68%\"\u003e\u003ch4\u003e$618,000.00\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd class=\"fr-thick\" style=\"text-align: right; width: 48.4324%; vertical-align: middle;\" valign=\"top\" width=\"31%\"\u003e\u003ch4\u003e\u003cstrong\u003eMinimum Investment Amount\u003c/strong\u003e\u003c/h4\u003e\u003ch4\u003e\u003cstrong\u003e(per investor)\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd class=\"fr-thick\" style=\"width: 3.2433%; text-align: center;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd class=\"fr-thick\" style=\"text-align: left; width: 48.3244%; vertical-align: middle;\" valign=\"top\" width=\"68%\"\u003e\u003ch4\u003e$500.00\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/table\u003e\u003cp style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003ch4 style=\"text-align: center;\"\u003eTerms\u003c/h4\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003ctable align=\"left\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd style=\"width: 48.2162%; text-align: right;\"\u003e\u003ch4\u003e\u003cstrong\u003eOffering Type\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"width: 3.2433%; text-align: center;\"\u003e:\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"width: 48.2681%;\" valign=\"top\" width=\"68%\"\u003e\u003ch4\u003eConvertible Promissory Notes\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"text-align: right; width: 48.2162%;\"\u003e\u003ch4\u003e\u003cstrong\u003eType of Equity Converted Into\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"text-align: center; width: 3.2433%;\"\u003e:\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"width: 48.2681%;\"\u003e\u003ch4\u003eCommon Stock\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"text-align: right; width: 48.2162%;\"\u003e\u003ch4\u003e\u003cstrong\u003eConversion Trigger\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"text-align: center; width: 3.2433%;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"width: 48.2681%;\"\u003e\u003ch4\u003e$3,000,000.00\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"text-align: right; width: 48.2162%;\"\u003e\u003ch4\u003e\u003cstrong\u003eMaturity Date\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"text-align: center; width: 3.2433%;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"width: 48.2681%;\"\u003e\u003ch4\u003eMay 01, 2026\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"text-align: right; width: 48.2162%;\"\u003e\u003ch4\u003e\u003cstrong\u003eValuation Cap\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"text-align: center; width: 3.2433%;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"width: 48.2681%;\"\u003e\u003ch4\u003e$25,000,000.00\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"text-align: right; width: 48.2162%;\"\u003e\u003ch4\u003e\u003cstrong\u003eDiscount Rate\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"text-align: center; width: 3.2433%;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"width: 48.2681%;\"\u003e\u003ch4\u003e12.0%\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style=\"text-align: right; width: 48.2162%;\"\u003e\u003ch4\u003e\u003cstrong\u003eAnnual Interest Rate\u003c/strong\u003e\u003c/h4\u003e\u003c/td\u003e\u003ctd style=\"text-align: center; width: 3.2433%;\"\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003cbr\u003e\u003c/td\u003e\u003ctd style=\"width: 48.2681%;\"\u003e\u003ch4\u003e4.85%\u003c/h4\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/table\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\" style=\"text-align: center;\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\"\u003e\u003cspan style=\"font-size: 18px;\"\u003e\u003cstrong\u003eWhat is a Convertible Note?\u003c/strong\u003e\u003c/span\u003e\u003c/p\u003e\u003cp dir=\"ltr\"\u003e\u003cspan style=\"font-size: 18px;\"\u003eA convertible note offers you the right to receive Common Stock in MedVector Corp.. The amount of \u003cspan style=\"font-size: 18px;\"\u003eCommon Stock\u003c/span\u003e you will receive in the future will be determined at the next equity round in which the Company raises at least $3,000,000.00 in a qualified equity financing. The highest conversion price per security is set based on a $25,000,000.00 \u0026nbsp;Valuation Cap or if less, then you will receive a 12.0% discount on the price the new investors are paying. \u0026nbsp;You also receive 4.85% interest per year added to your investment. \u0026nbsp;When the maturity date is reached, if the note has not converted then you are entitled to receive Common Stock equal to your investment and interest back at a price per security determined by dividing the Valuation Cap by the aggregate number of outstanding equity securities of the Company as of immediately prior (on a fully diluted basis).\u003c/span\u003e\u003c/p\u003e\u003cp dir=\"ltr\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp dir=\"ltr\"\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003e*Annual Interest Rate subject to adjustment of 10% bonus for StartEngine shareholders. See 10% Bonus below.\u003c/em\u003e\u003c/p\u003e\n\u003cp style=\"text-align:center;\"\u003e\u003cstrong\u003eVoting Rights of Securities Sold in this Offering\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eVoting Proxy. Should the convertible promissory notes sold in this offering convert into shares of Common Stock, each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.\u003c/p\u003e\n\u003cp style=\"text-align:center;\"\u003e\u003cstrong\u003e\u003cins\u003eInvestment Incentives and Bonuses*\u003c/ins\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLoyalty Bonus | 20% Bonus Interest\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAs you are an existing investor in MedVector, you are eligible for additional bonus interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTime-Based Investment Incentives\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEarly Bird\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eInvest within the first two weeks and receive 10% bonus interest.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus interest from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed. Crowdfunding investments made through a self-directed IRA cannot receive perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those perks because they would be receiving a benefit from their IRA account.\u003c/em\u003e\u003c/p\u003e\n\u003cp style=\"text-align:center;\"\u003e\u003cstrong\u003eThe 10% StartEngine Venture Club\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMedVector Corp. will offer a 10% additional bonus interest for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding, Inc. Venture Club bonus.\u003c/p\u003e\n\u003cp\u003eEligible StartEngine convertible note holders will receive a 10% increase in the annual interest rate on Convertible Promissory Notes in this Offering. This means your annual interest rate will be 5.335% instead of 4.85%.\u003c/p\u003e\n\u003cp\u003eThis 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.\u003c/p\u003e\n\u003cp\u003eEligible investors will also receive the Venture Club Bonus and the Loyalty Bonus in addition to the Early Bird bonus.\u003c/p\u003e\n"])</script><script>self.__next_f.push([1,"23:Tf59,"])</script><script>self.__next_f.push([1,"\u003cp\u003e\u003cem\u003e*Annual Interest Rate subject to adjustment of 10% bonus for StartEngine shareholders. See 10% Bonus below.\u003c/em\u003e\u003c/p\u003e\n\u003cp style=\"text-align:center;\"\u003e\u003cstrong\u003eVoting Rights of Securities Sold in this Offering\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eVoting Proxy. Should the convertible promissory notes sold in this offering convert into shares of Common Stock, each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.\u003c/p\u003e\n\u003cp style=\"text-align:center;\"\u003e\u003cstrong\u003e\u003cins\u003eInvestment Incentives and Bonuses*\u003c/ins\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLoyalty Bonus | 20% Bonus Interest\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAs you are an existing investor in MedVector, you are eligible for additional bonus interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTime-Based Investment Incentives\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEarly Bird\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eInvest within the first two weeks and receive 10% bonus interest.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus interest from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed. Crowdfunding investments made through a self-directed IRA cannot receive perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those perks because they would be receiving a benefit from their IRA account.\u003c/em\u003e\u003c/p\u003e\n\u003cp style=\"text-align:center;\"\u003e\u003cstrong\u003eThe 10% StartEngine Venture Club\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMedVector Corp. will offer a 10% additional bonus interest for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding, Inc. Venture Club bonus.\u003c/p\u003e\n\u003cp\u003eEligible StartEngine convertible note holders will receive a 10% increase in the annual interest rate on Convertible Promissory Notes in this Offering. This means your annual interest rate will be 5.335% instead of 4.85%.\u003c/p\u003e\n\u003cp\u003eThis 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.\u003c/p\u003e\n\u003cp\u003eEligible investors will also receive the Venture Club Bonus and the Loyalty Bonus in addition to the Early Bird bonus.\u003c/p\u003e\n"])</script><script>self.__next_f.push([1,"8:[\"$\",\"$L21\",null,{\"offeringData\":{\"id\":\"d50479f1-8824-4cea-a2ce-782675405bb9\",\"primaryId\":\"65e9de403f97f4590acb81b7\",\"externalId\":\"65e9de403f97f4590acb81b7\",\"entitySource\":\"PRIMARY\",\"slug\":\"medvector\",\"name\":\"MedVector\",\"content\":\"A clinical trial could save your life… \",\"categories\":[{\"id\":\"2b2c41ed-f782-41bf-91e5-67096a10c8e3\",\"name\":\"Health Tech\",\"label\":\"health-tech\",\"imageUrl\":\"https://d2j6gq8tvnyhoe.cloudfront.net/mobile/discover/0689c66e-f0b0-447b-860c-b0b188f531d8.png\"}],\"regulationType\":\"Reg CF\",\"offeringType\":\"convertible_note\",\"coverDesktopUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/images/startup_cover/desktop_MedVector_Cover_Image_V.1.jpg\",\"coverTombstoneUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/images/startup_cover/tombstone_MedVector_Cover_Image_V.1.jpg\",\"logoUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/images/startup_image/profile_medlogo.jpg\",\"videoUrl\":\"https://youtu.be/r8MN5CoACM0\",\"status\":\"closed\",\"maximumFundingAmount\":\"618000.00 USD\",\"previousRaiseTotal\":\"0.00 USD\",\"previousCrowdfundedRaiseTotal\":\"874284.75 USD\",\"previousRaiseInvestorCount\":0,\"valuation\":\"22000000.00 USD\",\"valuationCap\":\"25000000.00 USD\",\"amountRaised\":\"118732.51 USD\",\"endDate\":\"2024-08-20T06:59:59.999Z\",\"startDate\":\"2024-05-21T17:58:58.985Z\",\"showFundingGoal\":true,\"fundingGoal\":\"15000.00 USD\",\"minimumNumberOfSharesOffered\":0,\"maximumNumberOfSharesOffered\":0,\"minimumInvestmentAmount\":\"500.00 USD\",\"maximumInvestmentAmount\":\"618000.00 USD\",\"elevatorPitch\":\"MedVector utilizes telemedicine for clinical trials. Now patients can benefit from advanced medicine as a treatment option from their trusted doctor’s office. Our FDA and HIPAA-compliant platform unlocks access to potentially millions of patients, driving rapid clinical trial enrollment, and bringing lifesaving medications to those who need it, faster and more affordably. \\n \\nMedVector is currently operational, but pre-revenue.\",\"numberOfContributors\":57,\"numberOfInvestors\":57,\"showPercentCompleted\":true,\"website\":\"medvector.com\",\"terms\":\"$22\",\"team\":[{\"id\":\"0106ad30-365d-4cd2-88a8-0f60ea77f740\",\"fullName\":\"Dr. Dennis Patterson\",\"title\":\"Hospital Relations, Board Member \u0026 Co-Founder\",\"bio\":\"\u003cp\u003eDr. Patterson brings a wealth of knowledge from hospital management roles at Ernst \u0026amp; Young (UK) and was a founder of Wellspring Partners. He leads MedVector's hospital relationships.\u003c/p\u003e\\r\\n\",\"position\":3,\"twitterUrl\":\"\",\"linkedinUrl\":\"https://www.linkedin.com/in/dennis-pattterson-b48b455/\",\"facebookUrl\":\"\",\"founder\":true,\"profileImageUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/founders/images/profile_image/founder_dennismedv.jpg\"},{\"id\":\"18a4dc58-7af5-42d1-b847-0e4a16012600\",\"fullName\":\"Ian Leaman\",\"title\":\"Board Member, Fractional CFO\",\"bio\":\"\u003cp\u003eA Deloitte-trained Chartered Accountant with Board and Senior Finance Executive experience. Over 50 completed M\u0026amp;A's. Senior finance positions both in US and Internationally. FINRA registered Investment Banker (S.79).\u003c/p\u003e\\r\\n\u003cp\u003eIn addition to working approximately 7 hours per week for MedVector, Ian also splits his time working for other companies: Arkeytyp Holdings Ltd. (CFO), ~2 hours per week; Curriqunet (CFO), ~9 hours per week; AIDA Intelligent Solutions (fractional CFO), ~4 hours per week; Marula Capital LLC (Managing Director), ~3 hours per week; Legion Creative (Director), ~2 hours per week; BrandInc (fractional CFO), ~3 hours per week, and Duke \u0026amp; Leaman LLC ( Owner), ~10 hours per week.\u003c/p\u003e\\r\\n\",\"position\":1,\"twitterUrl\":\"\",\"linkedinUrl\":\"https://www.linkedin.com/in/ianleaman/\",\"facebookUrl\":\"\",\"founder\":false,\"profileImageUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/founders/images/profile_image/founder_ianmedmask_group.jpg\"},{\"id\":\"4fe8005d-1bca-4692-8e37-64e794e7c4f3\",\"fullName\":\"Scott Stout\",\"title\":\"CEO, Board Member \u0026 Founder\",\"bio\":\"\u003cp\u003eAn established healthcare innovator, named one of the Most Influential Healthcare Leaders in 2021 and recognized by Marquis’ Who’s Who in 2024, Scott brings financial expertise from Morgan Stanley where he aided several startups on their capital structures and go-to-market strategies. He excels at strategic direction, team building, and securing capital.\u003c/p\u003e\\r\\n\",\"position\":0,\"twitterUrl\":\"\",\"linkedinUrl\":\"https://www.linkedin.com/in/scott-stout-01992653/\",\"facebookUrl\":\"\",\"founder\":true,\"profileImageUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/founders/images/profile_image/founder_scottmedmask_group.jpg\"},{\"id\":\"1f13790a-8759-4201-a023-11dd077d7f90\",\"fullName\":\"Craig Lipset\",\"title\":\"Board Member\",\"bio\":\"\u003cp\u003eCraig Lipset leads at the forefront of innovation in clinical research and medicine development. He is an advisor to technology and biopharmaceutical companies, leading universities, and the venture community and was the Head of Clinical Innovation and Venture Partner at Pfizer. He continues to be one of the leading industry voices of decentralized clinical trials and innovation.\u003c/p\u003e\\r\\n\",\"position\":4,\"twitterUrl\":\"\",\"linkedinUrl\":\"https://www.linkedin.com/in/lipset/\",\"facebookUrl\":\"\",\"founder\":false,\"profileImageUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/founders/images/profile_image/founder_craigmedv.jpg\"},{\"id\":\"fc6ec87a-515c-46e8-9e53-d3e045cd6078\",\"fullName\":\"Ted Barduson\",\"title\":\"Chief Operating Officer, Board Member \u0026 Co-Founder \",\"bio\":\"\u003cp\u003eWith over 35 years in healthcare, Ted is an expert in scaling operations, revenue cycle management, and mergers \u0026amp; acquisitions. His passion lies in accelerating access to life-changing treatments.\u003c/p\u003e\\r\\n\",\"position\":2,\"twitterUrl\":\"\",\"linkedinUrl\":\"https://www.linkedin.com/in/tedbarduson/\",\"facebookUrl\":\"\",\"founder\":true,\"profileImageUrl\":\"https://d19j0qt0x55bap.cloudfront.net/production/startups/65e9de403f97f4590acb81b7/founders/images/profile_image/founder_tedmedmask_group.jpg\"}],\"debtInterestRate\":4.85,\"debtMaturityDate\":\"2026-05-01T00:00:00.000Z\",\"discountRate\":12,\"investorFeeRate\":3.5,\"investorFeeCap\":\"700.00 USD\",\"seFeeRate\":9,\"seIntlFeeRate\":9,\"ccFeeRate\":0,\"securitySymbol\":\"MVCNNP\",\"offeringCircularUrl\":\"https://www.sec.gov/Archives/edgar/data/1820902/000166516024000884/0001665160-24-000884-index.htm\",\"secUrl\":\"https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001820902\u0026owner=exclude\u0026action=getcompany\u0026Find=Search\",\"signToTradeDisclosureUrl\":\"https://www.startengine.com/signed-to-trade-disclosure\",\"offeringDetailsUrl\":\"https://startenginebetadev.s3.amazonaws.com/production/startups/65e9de403f97f4590acb81b7/documents/offering_details/edgar_1715881433_offering_memorandum.pdf\",\"issuerTitle\":\"CEO \u0026 Co-Founder\",\"issuerLocation\":\"CA\",\"stateIncorporated\":\"DE\",\"dateOfLaunch\":\"2024-05-21T17:58:58.985Z\",\"approvedAt\":\"2024-05-21T17:58:58.985Z\",\"issuerName\":\"MedVector Corp.\",\"addressLine1\":\"898 N. Pacific Coast Highway\",\"city\":\"El Segundo\",\"state\":\"CA\",\"zipcode\":\"90245\",\"numberOfHoursLeft\":-7996,\"allowCreditCards\":true,\"allowCryptoPayments\":false,\"company\":{\"id\":\"ec7fbf90-0883-4553-bd21-90abd367e09e\",\"legalName\":\"MedVector Corp.\",\"externalId\":\"65e9de443f97f401e15763f4\"},\"startengineCompany\":{\"id\":\"e7bc5349-4ea1-4ea3-845a-55de3a9134b3\",\"companyName\":\"StartEngine Capital, LLC\"},\"useAngelInvestmentSvc\":false,\"seBrokerDealer\":false,\"seSellingBrokerDealer\":false,\"escrowProvider\":{\"id\":\"79667ef6-9e1d-4549-8572-88d270e96abd\",\"name\":\"BRYN_MAWR\",\"label\":\"Bryn Mawr\",\"primaryEscrowProviderId\":\"617b62495aaa397a9fd44b75\"},\"escrowProviderStatus\":\"OPEN\",\"showSameRaiseTotals\":false,\"showTombstoneRaiseBar\":false,\"seBonusApplicable\":true,\"hideHighlights\":false,\"teamSectionDisabled\":false,\"commentsEnabled\":true,\"irregularUseOfProceeds\":\"The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Any expense labeled “Travel and Entertainment”. \",\"excludedStates\":[],\"accountHolderUserId\":\"65e9dd857254bf785dceb032\",\"securityName\":\"Common Stock\",\"valuationDetails\":\"Example - We have not undertaken any efforts to produce a valuation of the Company. The price of the shares merely reflects the opinion of the Company as to what would be fair market value.\",\"anticipatedAmount\":\"$$1,000,000+\",\"internationalInvestorsAllowed\":true,\"cashAndCashEquivalentsPriorYear\":\"430542.00 USD\",\"cashAndCashEquivalentsRecentYear\":\"64386.00 USD\",\"accountsReceivablePriorYear\":\"0.00 USD\",\"accountsReceivableRecentYear\":\"0.00 USD\",\"shortTermDebtPriorYear\":\"360140.00 USD\",\"shortTermDebtRecentYear\":\"392239.00 USD\",\"longTermDebtPriorYear\":\"0.00 USD\",\"longTermDebtRecentYear\":\"0.00 USD\",\"revenueAndSalesPriorYear\":\"0.00 USD\",\"revenueAndSalesRecentYear\":\"0.00 USD\",\"costOfGoodsSoldPriorYear\":\"0.00 USD\",\"costOfGoodsSoldRecentYear\":\"0.00 USD\",\"taxesPaidPriorYear\":\"0.00 USD\",\"taxesPaidRecentYear\":\"0.00 USD\",\"netIncomePriorYear\":\"-653737.00 USD\",\"netIncomeRecentYear\":\"-704633.00 USD\",\"totalAssetsPriorYear\":\"759063.00 USD\",\"totalAssetsRecentYear\":\"411528.00 USD\",\"conversion\":3000000,\"investmentAccountRequiredToComment\":true,\"offeringTermsDescription\":\"A convertible note offers you the right to receive Common Stock in MedVector. The amount of Common Stock you will receive in the future will be determined at the next equity round in which the Company raises at least $3,000,000.00 in a qualified equity financing. The highest conversion price per security is set based on a $25,000,000.00 Valuation Cap or if less, then you will receive a 12.00% discount on the price the new investors are paying. You also receive 4.85% interest per year added to your investment. When the maturity date is reached, if the note has not converted then you are entitled to receive Common Stock equal to your investment and interest back at a price per security determined by dividing the Valuation Cap by the aggregate number of outstanding equity securities of the Company as of immediately prior (on a fully diluted basis).\",\"perksAndOtherMaterialInformation\":\"$23\",\"convertibleName\":\"Common Stock\",\"internalAmountRaised\":\"118732.51 USD\",\"investorMatchedOffering\":false,\"hasCampaignPage\":true,\"tierLevel\":\"TIER_2\",\"restricted\":false,\"rewardsCap\":null,\"rolloverDetails\":[],\"lockedOnWaitlist\":false,\"partners\":[],\"retirementFundsOnly\":false,\"ceo\":\"Scott Stout\",\"issuerAddress\":\"898 N. Pacific Coast Highway, El Segundo, CA 90245\",\"hqLocation\":\"El Segundo, CA\",\"isOverMax\":false},\"data-sentry-element\":\"Body\",\"data-sentry-component\":\"BodyServerComponent\",\"data-sentry-source-file\":\"Body.server.jsx\"}]\n"])</script><div hidden id="S:0"><template data-dgst="BAILOUT_TO_CLIENT_SIDE_RENDERING"></template></div><script>$RC=function(b,c,e){c=document.getElementById(c);c.parentNode.removeChild(c);var a=document.getElementById(b);if(a){b=a.previousSibling;if(e)b.data="$!",a.setAttribute("data-dgst",e);else{e=b.parentNode;a=b.nextSibling;var f=0;do{if(a&&8===a.nodeType){var d=a.data;if("/$"===d)if(0===f)break;else f--;else"$"!==d&&"$?"!==d&&"$!"!==d||f++}d=a.nextSibling;e.removeChild(a);a=d}while(a);for(;c.firstChild;)e.insertBefore(c.firstChild,a);b.data="$"}b._reactRetry&&b._reactRetry()}};$RC("B:0","S:0")</script></body></html>